Inspiration

INSPIRE MEDICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inspire Medical Systems, Inc. - INSP

Retrieved on: 
Wednesday, January 10, 2024
District court, Court, KSF, Inspiration, INSP

NEW ORLEANS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 20, 2024 to file lead plaintiff applications in a securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP), if they purchased the Company’s shares between May 3, 2023 and November 7, 2023, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 20, 2024 to file lead plaintiff applications in a securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP), if they purchased the Company’s shares between May 3, 2023 and November 7, 2023, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the District of Minnesota.
  • If you purchased shares of Inspire and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-insp/ to learn more.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 20, 2024.

INSP Investors: Contact Robbins LLP for Information About the Inspire Medical Systems, Inc. Class Action Lawsuit

Retrieved on: 
Wednesday, January 10, 2024
SAN, Obstructive sleep apnea, Patient, LLP, OSA, News, Inspiration, Person, INSP

Inspire Medical is a medical technology company that develops and commercializes minimally invasive products for patients with obstructive sleep apnea (“OSA”).

Key Points: 
  • Inspire Medical is a medical technology company that develops and commercializes minimally invasive products for patients with obstructive sleep apnea (“OSA”).
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • On November 7, 2023, Inspire Medical issued its results for the third quarter of 2023, acknowledging a decline in prior authorization submissions for patients seeking Inspire therapy.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Inspire Medical Systems, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2023 Financial Results on February 6, 2024

Retrieved on: 
Tuesday, January 9, 2024
Inspiration, Webcast, Video game

MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2023 after the close of trading on Tuesday, February 6.

Key Points: 
  • MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2023 after the close of trading on Tuesday, February 6.
  • Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
  • A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2023 earnings call webcast.
  • If you plan to ask a question, please use the following link: Inspire's Q4 2023 earnings call.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Inspire Medical Systems, Inc. (INSP)

Retrieved on: 
Monday, January 8, 2024
Class Action Lawsuit, Professional Services, Legal, Suite, GPM, Court, News, Inspiration, OSA, Defendant, Tobacco

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 20, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP ) common stock between May 3, 2023 and November 7, 2023, inclusive (the “Class Period”).

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 20, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP ) common stock between May 3, 2023 and November 7, 2023, inclusive (the “Class Period”).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Inspire Medical’s stock price fell $31.79, or 19.8%, to close at $129.65 per share on November 8, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance

Retrieved on: 
Monday, January 8, 2024
Inspiration, Growth, Conference, Patient, Obstructive sleep apnea, Annual report, Pharmaceutical industry

MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023, and provided its initial full year 2024 guidance.

Key Points: 
  • MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023, and provided its initial full year 2024 guidance.
  • “Throughout 2023, we demonstrated improved operating leverage as our sales growth outpaced operating expenses.
  • As a result, we expect to announce a profitable fourth quarter when we report our full financial results, currently planned for February 6, 2024.”
    The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until Inspire reports its full financial results for 2023 in its Annual Report on Form 10-K.
    Inspire previously announced its participation in the 41st Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, including a formal company presentation at 7:30 a.m. P.T.
  • on Monday, January 8, 2024.

INSPIRE MEDICAL SYSTEMS, INC. (NYSE: INSP) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Inspire Medical Systems, Inc.

Retrieved on: 
Monday, January 8, 2024
Obstructive sleep apnea, Food, Court, News, Complaint, Inspiration, Advertising, OSA, Action Replay, Patient, Sleep apnea, District court, Tobacco

If you purchased or acquired Inspire Medical common stock, and/or would like to discuss your legal rights and options please visit Inspire Medical Systems, Inc.

Key Points: 
  • If you purchased or acquired Inspire Medical common stock, and/or would like to discuss your legal rights and options please visit Inspire Medical Systems, Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you purchased or acquired Inspire Medical common stock, and/or would like to discuss your legal rights and options please visit Inspire Medical Systems, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Inspire Medical Systems, Inc. Investors With Large Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against INSP

Retrieved on: 
Friday, January 5, 2024
Class Action Lawsuit, Professional Services, Legal, Inspiration, LLP, OSA, Patient, Obstructive sleep apnea, Person, News, INSP

Inspire Medical is a medical technology company that develops and commercializes minimally invasive products for patients with obstructive sleep apnea (“OSA”).

Key Points: 
  • Inspire Medical is a medical technology company that develops and commercializes minimally invasive products for patients with obstructive sleep apnea (“OSA”).
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • On November 7, 2023, Inspire Medical issued its results for the third quarter of 2023, acknowledging a decline in prior authorization submissions for patients seeking Inspire therapy.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Inspire Medical Systems, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Inspire Medical Systems, Inc. (INSP)

Retrieved on: 
Friday, January 5, 2024
Class Action Lawsuit, Professional Services, Legal, Telephone, Suite, Court, News, Inspiration, Law, OSA, Defendant

Investors suffering losses on their Inspire Medical investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Inspire Medical investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On this news, Inspire Medical’s stock price fell $31.79, or 19.8%, to close at $129.65 per share on November 8, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Inspired Entertainment, Inc. (INSE)

Retrieved on: 
Thursday, January 4, 2024
Bank statement, Inspiration, News, Private investigator

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Inspired Entertainment, Inc. (“Inspired Entertainment” or the “Company”) (NASDAQ: INSE ).

Key Points: 
  • NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Inspired Entertainment, Inc. (“Inspired Entertainment” or the “Company”) (NASDAQ: INSE ).
  • The investigation concerns whether Inspired Entertainment and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • As such, Inspired Entertainment determined that the Company’s financial statements for the financial period starting on January 1, 2021 should not be relied upon.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Inspire Medical Systems, Inc. (INSP) Investors

Retrieved on: 
Wednesday, January 3, 2024
Class Action Lawsuit, Professional Services, Legal, Suite, GPM, Court, News, Inspiration, OSA, Defendant

Inspire Medical investors have until February 20, 2024 to file a lead plaintiff motion.

Key Points: 
  • Inspire Medical investors have until February 20, 2024 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Inspire Medical’s stock price fell $31.79, or 19.8%, to close at $129.65 per share on November 8, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.